SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Cash from Operations of 8800000.0 for Q1 2026, up 2.98% year-over-year from 8545610.28 in Q1 2025, and down 78.43% quarter-over-quarter from 4932000.0 in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Cash from Operations for 17 consecutive years, with 8800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 2.98% year-over-year to 8800000.0; the TTM figure through Mar 2026 stood at 28130000.0 (up 16.56% YoY), while the FY2025 annual figure was 28400000.0, up 19.78% from the prior year.
- Cash from Operations fell to 8800000.0 in Q1 2026 per SLS's latest filing, from 4932000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 4825000.0 in Q4 2023 and bottomed at 12127000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 7518882.35 across 5 years, with a median of 7153000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations plunged 69.61% — and 2025, when it soared 31.05%.
- SELLAS Life Sciences' Cash from Operations stood at 5152000.0 in 2022, then climbed by 6.35% to 4825000.0 in 2023, then sank by 48.25% to 7153000.0 in 2024, then jumped by 31.05% to 4932000.0 in 2025, then tumbled by 78.43% to 8800000.0 in 2026.
- Business Quant data shows SLS's Cash from Operations at 8800000.0 in Q1 2026, 4932000.0 in Q4 2025, and 7068000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | -7.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.59 Mn |
| Mar 31, 2026 | -8.85 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Sep 30, 2023 | -6.89 Mn |
| Jun 30, 2023 | -7.57 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Jun 30, 2022 | -5.76 Mn |
| Mar 31, 2022 | -7.15 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Sep 30, 2021 | -5.88 Mn |